Back to all use cases

Competitor Landscape Analysis

Map competitive positioning and identify strategic opportunities in your therapeutic area.

Prompt

Create a competitive landscape map for immuno-oncology companies showing market share vs innovation score. Highlight companies with Phase 3+ assets in checkpoint inhibitor combinations.

Sample Copilot Response

98s $0.39

Based on comprehensive market analysis, I can provide you with a competitive landscape overview for the immuno-oncology sector.

Market Leaders by Share and Innovation

Dominant Players (High Market Share + High Innovation): Bristol Myers Squibb, Roche, Merck & Co., and Johnson & Johnson are expected to hold the largest market shares in oncology drugs in 2024, with Merck's Keytruda earning more than $17 billion. These companies also rank among the top R&D spenders globally.

**Innovation Leaders by R&D Investment (2024):**

  • Merck & Co. - $30.53B (secured top spot for pharmaceutical R&D investment)
  • Roche - $15.73B
  • Johnson & Johnson - $15.08B
  • AstraZeneca and Novartis - among top performers demonstrating exceptional R&D effectiveness

Market Dynamics and Size

The immuno-oncology market size is estimated at $24.17 billion in 2024 and is expected to grow at a CAGR of 16.5% to reach $111.64 billion by 2034. Immune checkpoint inhibitors dominate with an overwhelming 91.4% market share in 2024, expected to grow to 93.7% by 2034.

Companies with Phase 3+ Checkpoint Inhibitor Combinations

**Advanced Combination Programs:**

  • <strong>Merck:</strong> Kicked off Phase 3 trials for four hematology and oncology candidates, continuing Keytruda combination development
  • <strong>AstraZeneca:</strong> Imfinzi (durvalumab) became the first approved regimen for limited-stage small cell lung cancer after platinum-based chemotherapy and radiation
  • <strong>Bristol Myers Squibb:</strong> The RELATIVITY-047 phase III trial demonstrated remarkable synergy with anti-PD-1 and anti-LAG-3 combinations, with relatlimab approved by FDA
  • <strong>Roche:</strong> FDA approved Tecentriq Hybreza, the first subcutaneous PD-(L)1 inhibitor in September 2024
  • <strong>ImmunityBio/BeiGene:</strong> Conducting confirmatory Phase 3 trial combining tislelizumab and ANKTIVA

Emerging Combination Strategies: Antiangiogenic agents targeting the VEGF-VEGFR pathway are currently among the few combination partners clinically proven to improve checkpoint inhibitor efficacy. Multiple Phase II/III trials are assessing dual LAG-3 + PD-1 therapy.

Innovation Score Considerations

**High Innovation Indicators:**

  • Top performers like Roche (100), Novo Nordisk (98.7), Eli Lilly (95.1), AstraZeneca (94.4), and Novartis (93.2) demonstrate research excellence
  • Companies investing in novel mechanisms of action show higher returns, with novel MoAs generating 37.3% of revenue despite comprising only 23.5% of pipelines

**Market Positioning Framework:**

  • <strong>High Share/High Innovation:</strong> Merck, Roche, BMS, J&J
  • <strong>High Innovation/Growing Share:</strong> AstraZeneca, Novartis, Eli Lilly
  • <strong>Emerging Players:</strong> ImmunityBio, smaller biotechs with novel combinations

The landscape shows consolidation around established players with strong checkpoint inhibitor franchises, while innovation increasingly focuses on combination therapies to overcome resistance and expand patient populations.

Learn more

Understanding your competitive position requires analyzing multiple dimensions—pipeline strength, market presence, partnership strategy, and innovation velocity. PharmaDB provides the data and visualization tools to map competitive landscapes and identify white space opportunities.

Key benefits:

  • Visualize competitive positioning across key strategic dimensions
  • Track competitor pipeline progress and partnership activity
  • Identify underserved patient segments and market gaps
  • Benchmark your capabilities against industry leaders

Perfect for: Strategic planning teams, competitive intelligence analysts, and business development professionals tracking market dynamics.

Competitive dimensions analyzed

Pipeline strength assessment

Evaluate competitor R&D capabilities:

  • Asset quality - Novel mechanisms, differentiation potential, clinical validation
  • Development velocity - Time in phase, trial design efficiency, regulatory success rates
  • Portfolio breadth - Therapeutic area coverage, indication diversity, stage balance
  • Innovation index - First-in-class assets, platform technologies, scientific partnerships

Market positioning analysis

Understand current competitive standing:

  • Market share - Sales performance, prescription volume, territory coverage
  • Commercial presence - Sales force size, marketing spend, physician relationships
  • Brand strength - Awareness, preference, loyalty metrics
  • Pricing power - Net price realization, discount patterns, payer access

Strategic intent mapping

Anticipate competitor moves:

  • Partnership patterns - Licensing appetite, collaboration terms, preferred deal structures
  • M&A activity - Acquisition targets, integration success, strategic rationale
  • Geographic expansion - Market entry timing, local partnership strategy
  • Technology investments - Digital health, AI/ML, precision medicine capabilities

Turn analysis into strategy

Use competitive insights to:

  • Identify positioning gaps and differentiation opportunities
  • Time market entry to avoid direct competition
  • Target partnership discussions with strategically aligned companies
  • Adjust clinical development strategy based on competitive learnings

Real-world impact

Companies using PharmaDB’s competitive intelligence report:

  • 3x faster competitive landscape assessments
  • Better positioning in partnership negotiations
  • Earlier identification of emerging threats
  • More focused portfolio strategy and resource allocation